Meeting
2023 ASCO Annual Meeting
Deciphering primary and acquired immunotherapy resistance with whole genome and transcriptome analysis (WGTA).
Authors
Sofia Genta
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Sofia Genta , Jeff Bruce , Xuan Li , Sam Felicen , Albiruni Ryan Abdul Razak , Samuel Saibil , Marcus O. Butler , Philippe L. Bedard , Bernard Lam , Ming Sound Tsao , Wey Liang Leong , Alexandra Easson , Ben X Wang , Ilinca Lungu , David Paul Goldstein , Aaron Richard Hansen , Lawson Eng , Trevor John Pugh , Lillian L. Siu , Anna Spreafico
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2602)
DOI
10.1200/JCO.2023.41.16_suppl.2602
Abstract #
2602
Poster Bd #
444
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
First Author: Emil Lou
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek